SCHEMBL6849128

SCHEMBL6849128

CCOC(=O)c1cn(Cc2cccc3ccccc23)nc1C(=O)CC(C)C

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CDC25B P30305 2/20 0.44
▸ ALDH1A1 P00352 4/20 0.43
▸ MAPT P10636 3/20 0.43
▸ LMNA P02545 2/20 0.43
▸ HPGD P15428 1/20 0.43
▸ CDC25A P30304 1/20 0.42
▸ CDC25C P30307 1/20 0.42
▸ RAB9A P51151 3/20 0.41
▸ SMN1; SMN2 Q16637 2/20 0.41
▸ NFKB1 P19838 1/20 0.41
▸ NFKB2 Q00653 1/20 0.41
▸ RELA Q04206 1/20 0.41
▸ KDM4E B2RXH2 5/20 0.41
▸ TDP1 Q9NUW8 2/20 0.41
▸ FNTA P49354 1/20 0.40
▸ FNTB P49356 1/20 0.40
▸ KMT2A Q03164 5/20 0.40
▸ GAA P10253 2/20 0.39
▸ GLA P06280 1/20 0.39
▸ MAPK1 P28482 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6842431 0.92 LMNA (0.46) CDC25BALDH1A1MAPTLMNAHPGD
SCHEMBL6842436 0.74 CDC25B (0.57) CDC25BALDH1A1MAPTLMNAHPGD
SCHEMBL3606815 0.72 MAPT (0.46) CDC25BALDH1A1MAPTLMNAHPGD
SCHEMBL6848160 0.70 MAPK8 (0.46) ALDH1A1MAPTLMNAHPGDSMN1; SMN2
SCHEMBL3180834 0.68 SLC22A12 (0.47) CDC25BALDH1A1MAPTLMNAHPGD
SCHEMBL277672 0.67 CDC25B (0.82) CDC25BALDH1A1MAPTHPGDCDC25A
SCHEMBL15815752 0.66 CYP19A1 (0.48) CDC25BALDH1A1MAPTLMNAHPGD
SCHEMBL28859320 0.66 PARP1 (0.44) LMNASMN1; SMN2TDP1KMT2AL3MBTL1
SCHEMBL28740610 0.66 ALDH1A1 (0.53) ALDH1A1LMNAHPGDRAB9ASMN1; SMN2
SCHEMBL4884114 0.65 NPSR1 (0.50) ALDH1A1MAPTLMNARAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6770646-B2 PYRROLO-, THIENO-, FURANO-AND PYRAZOLO-(3,4-D)-PYRIDAZINONES; USED FOR TREATING REVERSIBLE OBSTRUCTIVE AIRWAYS DISEASE AND EFFECTING IMMUNOSUPPRESSION ASTRAZENECA AB (SE) 2004-08-03 — — US disclosed
EP-1036076-B1 NOVEL COMPOUNDS ASTRAZENECA UK LTD (GB) 2002-09-04 — — EP disclosed
US-20020099055-A1 Novel compounds ASTRAZENECA AB. 2002-07-25 — — US disclosed
US-6342601-B1 TREATING ALLOGRAFT REJECTION, RHEUMATOID ARTHRITIS ASTRAZENECA AB (SE) 2002-01-29 — — US disclosed
EP-1036076-A1 NOVEL COMPOUNDS AstraZeneca UK Limited (GB) 2000-09-20 — — EP disclosed
WO-1999029695-A1 NOVEL COMPOUNDS ASTRAZENECA UK LIMITED (GB) 1999-06-17 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020099055-A1 Novel compounds THPO, CYP4B1, CYP3A4 CDC25B 1460/4885ALDH1A1 2122/4885MAPT 1404/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback